Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4)…
Have you ever thought about taking part in a Medical Trial? By registering your details with MedTrials.co.uk, we are able to send your details directly to companies who are looking for volunteers to take part in their medical research studies.
Information about you is kept on a register that CROs, Pharmaceutical companies and Clinical Investigators can access to contact you regarding individual studies.
Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4)…
Ira Pastor, CEO of Bioquark, Inc., speaks to MNT about his team’s controversial plans to restore life to people who have been declared brain dead. Powered by WPeMatico
The vast majority of children in a large clinical trial continued to tolerate peanuts for 4 years after it had ended, new research shows. Powered by WPeMatico
When an investigational prescription drug shows promise for treating a serious illness or filling an unmet medical need, the Food and Drug Administration (FDA) has special programs available to… Powered by WPeMatico
Scientists say they have validated a “surrogate endpoint” – a reliable statistical shortcut in a clinical trial – that could accelerate testing of new adjuvant therapies aimed at reducing deaths from… Powered by WPeMatico
Alexion Pharmaceuticals, Inc. and Sema4 have announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion’s rare disease SmartPanel analytics with Sema4’s proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and […]
Galapagos NV has announced positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLORA phase IIa trial. FLORA was an exploratory, randomized, double-blind, placebo-controlled trial investigating a once-daily oral dose of GLPG1690. The drug candidate was administered for 12 weeks in 23 IPF patients, 17 of whom received […]
